About the Company
Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease. Keryx is developing ZerenexTM (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes.
The Phase 3 clinical program of ZerenexTM for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease is being conducted pursuant to a Special Protocol Assessment (SPA) agreement with the FDA. Keryx is headquartered in New York City. Keryx is headquartered in New York City.
Keryx Biopharmaceuticals KERX reported a loss of 44 cents per share in the fourth quarter of 2014, much wider than both the Zacks Consensus Estimate of a loss of 38 cents and the year-ago quarter figure of 21 cents. Keryx...
Keryx Biopharmaceuticals, Inc. (KERX) is scheduled to report its fourth-quarter and full-year 2014 results on Feb 27, 2015. Keryx’s track record has been dismal in the first nine months of 2014 with the company reporting wider-than-expected losses in all...
Keryx Biopharmaceuticals, Inc. to Host Conference Call on Fourth Quarter and Year End 2014 Financial Results
Investor Conference Call to be Held Friday, February 27th at 8:00am ET- Keryx Biopharmaceuticals, Inc. (KERX), a biopharmaceutical company focused on bringing innovative therapies to market for patients with renal disease, today announced that a conference call will be...
Keryx Biopharmaceuticals Announces Commercial Launch of AURYXIA(TM) (ferric citrate) Tablets in the United States
Launches “Keryx Patient Plus” for Reimbursement Support and Patient Access Keryx Biopharmaceuticals, Inc. (KERX) (the “Company”) today announced it has begun shipping AURYXIA(TM) (ferric citrate) tablets to wholesalers in the U.S. Auryxia is approved for the control of serum...